课题基金 / 基金详情

Targeting beta-catenin in liver pathology: Novel Interactions, Novel Paradigms

Targeting beta-catenin in liver pathology: Novel Interactions, Novel Paradigms
靶向肝脏病理学中的 β-连环蛋白:新的相互作用,新的范式
批准号:
9084550
负责人:
Satdarshan Singh Monga
金额:
$32.83万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2018-06-30

项目摘要

项目成果

Satdarshan Singh Monga的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Wnt/ß-catenin signaling is pertinent in liver biology in regulating zonation, regeneration, development and metabolism. However aberrations in this pathway have been reported in hepatic fibrosis, hepatic injury, hepatoblastomas and hepatocellular cancer (HCC). Targeting ß-catenin in HCC is imminent. It is the 3rd fatal cancer worldwide and its incidence and associated death rates have steadily increased since the 1980s. Cellular & molecular basis of HCC is poorly understood. Wnt signaling has been deemed active in 17-40% of HCCs due to various reasons and around 20-40% of all HCCs harbor monoallelic somatic mutations in the exon-3 of the ß-catenin gene (CTNNB1) that encodes for a non-serine/threonine phosphorylatable, stable and constitutively active protein, making it an attractive therapeutic target. We have made several important and some paradoxical observations over the last few years including identification of novel interactions and cross-regulations between ß-catenin and other molecules. These may have significant biological and translational implications mandating an in-depth analysis that may have widespread implications in not just HCC but other hepatic pathologies where ß-catenin targeting may be of essence such as hepatic fibrosis, injury and metabolic syndrome. The overarching hypothesis of the proposal is that therapeutic targeting of ß-catenin must take into account existing redundancies and crosstalk with specific signaling pathways, which need to be comprehensively elucidated. We will test these hypotheses in three distinct but thematically related aims. In aim 1, we will investigate the mechanism of oxidative stress dependent enhanced hepatocarcinogenesis in ß-catenin conditional knockout mice (Hep-ß-Cat KO) to address if enhanced HCC is a murine 'artifact' due to the role of ß-catenin in vitamin C biosynthesis in murine hepatocytes. We identified a novel role of ß-catenin signaling in vitamin C biosynthesis in the murine liver, whic is a known major antioxidant. Unlike humans and primates, rodents synthesize vitamin C in the hepatocytes and regular mouse chow is devoid of ascorbic acid. We hypothesize that increased HCC and oxidative stress in Hep-ß-Cat KO is due to compromised vitamin C biosynthesis and its normalization will alleviate HCC and demonstrate ß-catenin to be a global therapeutic target in HCC. In aim 2 we will investigate mechanism and biological implications of PDGFRα upregulation and activation after ß-catenin inhibition in HCC cells. We hypothesize that PDGFRα upregulation along with the activation of its specific downstream signaling arm is an important mechanism that will allow growth of HCC after ß-catenin inhibition and that understanding the role and regulation of this phenomena will bear significantly on efficacious HCC treatment. In aim 3, we will investigate the role and regulation of ?-catenin stabilization following inhibition of ß-catenin expression in the liver. We hypothesize that ?-catenin stabilization during ß-catenin inhibition in HCC will prevent any untoward effect related to disruption of cell-cell adhesion. All the proposed studies in the grant will utilize a balance of i vitro and in vivo set of experiments and the expected outcomes will be highly relevant and translational.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pittsburgh Liver Research Center
Pittsburgh Liver Research Center
Pittsburgh Liver Center Admin Core
Pittsburgh Liver Research Center
海外基金